01099 SINOPHARM
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2024) | |||
| Current | 1.39X | Oper Margin | 2.7% |
|---|---|---|---|
| LT Debt/Equity | 15.1% | Net Margin | 1.2% |
| Total Debt/Equity | 96.8% | Return on Equity | 8.9% |
| Price/Book | 0.70X | Return on Assets | 1.8% |
| (HKD 18.780) | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
| Net Profit (MHKD) | 7,497.34 | 9,979.05 | 9,558.96 | 9,489.60 | 8,529.86 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | -24.9 | +4.4 | +0.7 | +11.3 | +22.0 |
| Earnings Per Share (HKD) | 2.403 | 3.198 | 3.063 | 3.041 | 2.742 |
| Earnings Per Share Growth (%) | -24.9 | +4.4 | +0.7 | +10.9 | +16.5 |
| Dividend Per Share (HKD) | 0.739 | 0.956 | 0.900 | 0.872 | 0.839 |
| P/E* (X) | 7.82 | 5.87 | 6.13 | 6.18 | 6.85 |
| Yield (%) | 3.94 | 5.09 | 4.79 | 4.64 | 4.47 |
| Dividend Share (%) | 30.76 | 29.90 | 29.38 | 28.68 | 30.62 |
| Book NAV (HKD) | 26.883 | 26.342 | 24.456 | 24.255 | 21.434 |
| Auditors' Opinion | Unqualified | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2025-07-21 21:40:20
Latest Result
| (RMBMn) | 2024-12 | 2023-12 | Chg* (%) | 2022-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 584,508 | 596,570 | -2.0 | 552,148 |
| Operating Result | 12,712 | 17,892 | -29.0 | 19,399 |
| Associates | 1,199 | 1,107 | +8.3 | 1,067 |
| Profit Before Taxation | 14,001 | 19,512 | -28.2 | 18,564 |
| Taxation | 3,577 | 4,502 | -20.5 | 4,218 |
| Profit /( Loss) After Taxation | 10,424 | 15,010 | -30.6 | 14,345 |
| Minority Interests | 3,374 | 5,956 | -43.4 | 5,820 |
| Net Profit | 7,050 | 9,054 | -22.1 | 8,526 |
| Earnings Per Share () | 2.4025 | 3.1977 | -24.9 | 3.0631 |
| Dividend Per Share () | 0.7390 | 0.9560 | -22.7 | 0.9000 |
| Announcement Date | 2025-03-24 | 2024-03-25 | NA | 2023-03-27 |
* Annualised
Last Update Time: 2025-07-21 21:40:25
